Telerehabilitation Approaches in Chronic Obstructive Pulmonary Patients

Comparison of the Effectiveness of Different Telerehabilitation Approaches in Chronic Obstructive Pulmonary Patients

Pulmonary rehabilitation (PR) is a first-line management strategy in chronic obstructive pulmonary patients (COPD) as it reduces shortness of breath, increases exercise capacity, and improves health-related quality of life. However, 8-50% of patients referred to PR do not participate at all, while 10-32% of those who start do not complete the program. Barriers to participation and completion include difficulty in accessing the program, poor mobility, lack of transport, and travel costs. Telerehabilitation is defined as the provision of rehabilitation services through telecommunication technology, including telephone, internet and video conference communications between the patient and the healthcare provider. Different technologies (from phone to video conferencing) have been tested in patients with COPD to enhance daily activities, exercise training and walking prescription. All of them showed positive effects on exercise tolerance, dyspnea, physical activity and quality of life. However, there is no study about which telerehabilitation program is more effective on COPD patients. The aim of this study is to investigate which telerehabilitation approach is more effective in COPD.

Study Overview

• Status: Unknown
• Conditions: Telerehabilitation; COPD
• Intervention / Treatment: Other: videoconference-based; Other: video-based

• Study Type: Interventional
• Enrollment (Anticipated): 54
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Turkey
  • Istanbul, Turkey
    • Recruiting
    • Istanbul Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Being diagnosed with COPD (FEV1 / FVC <70% in the stable phase of the disease)
• Age > 18 years old
• Have the ability to use a smartphone

Exclusion Criteria:

• Musculoskeletal disorders that limit exercise
• Dizziness, significant sensory or motor impairments, dementia or terminal illnesses that prevent education
• Serious comorbidities such as unstable heart disease, irregular diabetes, known malignant disease, any other disease that makes the patient unsuitable for participation in the study.
• Incompatible patient
• Severe vision or hearing impairment
• Unwillingness or inability to follow the protocol
• Have had a COPD exacerbation in the previous 6 weeks

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: study group; Videoconference-based	Other: videoconference-based; Exercises will be done 3 days a week for 6 weeks, with the help of a physiotherapist via video conference.
Experimental: control group; Video-based	Other: video-based; The exercise video will be sent to the patients and they will do it 3 days a week for 6 weeks. The subjects will be asked to keep an exercise diary and the status of the diaries will be followed by calling once a week.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
6 minute walk test(6MWT)	6 week
Pulmonary function testing	6 week

Secondary Outcome Measures

Outcome Measure	Time Frame
30-Second Chair Stand Test	6 week
Time Up and Go Test	6 week
Copd Assessment Test	6 week
St George's Respiratory Questionnaire	6 week
Hospital Anxiety and Depression Scale	6 week
Medical Research Council Scale	6 week
Short Physical Performance Battery	6 week
International Physical Activity Questionnaire-Short Form	6 week
Static Lung Volumes	6 week

Collaborators and Investigators

• Sponsor: Saglik Bilimleri Universitesi

Study record dates

Study Major Dates

• Study Start (Actual): January 1, 2021
• Primary Completion (Anticipated): March 1, 2021
• Study Completion (Anticipated): December 1, 2021

Study Registration Dates

• First Submitted: January 2, 2021
• First Submitted That Met QC Criteria: January 2, 2021
• First Posted (Actual): January 5, 2021

Study Record Updates

• Last Update Posted (Actual): January 6, 2021
• Last Update Submitted That Met QC Criteria: January 4, 2021
• Last Verified: January 1, 2021

More Information

Terms related to this study

• Other Study ID Numbers: TeleCOPD

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No